Can Fite Biopharma Ltd ADR is a biotechnology business based in the US. Can Fite Biopharma Ltd ADR shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $2.01 – an increase of 1.01% over the previous week. Can Fite Biopharma Ltd ADR employs 8 staff and has a trailing 12-month revenue of around $667,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.01 |
|---|---|
| 52-week range | $1.83 - $4.69 |
| 50-day moving average | $2.26 |
| 200-day moving average | $2.41 |
| Wall St. target price | $13.33 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.56 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.03 from 2024-11-19
| 1 week (2024-11-14) | 2.01% |
|---|---|
| 1 month (2024-10-21) | -30.72% |
| 3 months (2024-08-21) | -12.12% |
| 6 months (2024-05-21) | -17.31% |
| 1 year (2023-11-21) | -5.14% |
|---|---|
| 2 years (2022-11-21) | -75.68% |
| 3 years (2021-11-19) | 12.1 |
| 5 years (2019-11-21) | 26 |
| Revenue TTM | $667,000 |
|---|---|
| Gross profit TTM | $810,000 |
| Return on assets TTM | -57.46% |
| Return on equity TTM | -157.62% |
| Profit margin | 0% |
| Book value | $0.00 |
| Market Capitalization | $11.9 million |
TTM: trailing 12 months
We're not expecting Can Fite Biopharma Ltd ADR to pay a dividend over the next 12 months.
Can Fite Biopharma Ltd ADR's shares were split on a 1:10 basis on 8 January 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can Fite Biopharma Ltd ADR shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Can Fite Biopharma Ltd ADR shares which in turn could have impacted Can Fite Biopharma Ltd ADR's share price.
Over the last 12 months, Can Fite Biopharma Ltd ADR's shares have ranged in value from as little as $1.83 up to $4.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can Fite Biopharma Ltd ADR's is 0.567. This would suggest that Can Fite Biopharma Ltd ADR's shares are less volatile than average (for this exchange).
Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.